Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Abstract Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population...
Published in: | Blood Cancer Journal |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Springer Science and Business Media LLC
2021
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1038/s41408-021-00480-w http://www.nature.com/articles/s41408-021-00480-w.pdf http://www.nature.com/articles/s41408-021-00480-w |
id |
crspringernat:10.1038/s41408-021-00480-w |
---|---|
record_format |
openpolar |
spelling |
crspringernat:10.1038/s41408-021-00480-w 2023-05-15T16:48:13+02:00 Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A. Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S. Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G. M. Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi 2021 http://dx.doi.org/10.1038/s41408-021-00480-w http://www.nature.com/articles/s41408-021-00480-w.pdf http://www.nature.com/articles/s41408-021-00480-w en eng Springer Science and Business Media LLC https://creativecommons.org/licenses/by/4.0 https://creativecommons.org/licenses/by/4.0 CC-BY Blood Cancer Journal volume 11, issue 5 ISSN 2044-5385 Oncology Hematology journal-article 2021 crspringernat https://doi.org/10.1038/s41408-021-00480-w 2022-01-04T16:17:35Z Abstract Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy. Article in Journal/Newspaper Iceland Springer Nature (via Crossref) Blood Cancer Journal 11 5 |
institution |
Open Polar |
collection |
Springer Nature (via Crossref) |
op_collection_id |
crspringernat |
language |
English |
topic |
Oncology Hematology |
spellingShingle |
Oncology Hematology Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A. Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S. Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G. M. Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
topic_facet |
Oncology Hematology |
description |
Abstract Monoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy. |
format |
Article in Journal/Newspaper |
author |
Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A. Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S. Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G. M. Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi |
author_facet |
Rögnvaldsson, Sæmundur Love, Thorvardur Jon Thorsteinsdottir, Sigrun Reed, Elín Ruth Óskarsson, Jón Þórir Pétursdóttir, Íris Sigurðardóttir, Guðrún Ásta Viðarsson, Brynjar Önundarson, Páll Torfi Agnarsson, Bjarni A. Sigurðardóttir, Margrét Þorsteinsdóttir, Ingunn Ólafsson, Ísleifur Þórðardóttir, Ásdís Rósa Eyþórsson, Elías Jónsson, Ásbjörn Björnsson, Andri S. Gunnarsson, Gunnar Þór Pálsson, Runólfur Indriðason, Ólafur Skúli Gíslason, Gauti Kjartan Ólafsson, Andri Hákonardóttir, Guðlaug Katrín Brinkhuis, Manje Halldórsdóttir, Sara Lovísa Ásgeirsdóttir, Tinna Laufey Steingrímsdóttir, Hlíf Danielsen, Ragnar Dröfn Wessman, Inga Kampanis, Petros Hulcrantz, Malin Durie, Brian G. M. Harding, Stephen Landgren, Ola Kristinsson, Sigurður Yngvi |
author_sort |
Rögnvaldsson, Sæmundur |
title |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_short |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_full |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_fullStr |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_full_unstemmed |
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
title_sort |
iceland screens, treats, or prevents multiple myeloma (istopmm): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies |
publisher |
Springer Science and Business Media LLC |
publishDate |
2021 |
url |
http://dx.doi.org/10.1038/s41408-021-00480-w http://www.nature.com/articles/s41408-021-00480-w.pdf http://www.nature.com/articles/s41408-021-00480-w |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Blood Cancer Journal volume 11, issue 5 ISSN 2044-5385 |
op_rights |
https://creativecommons.org/licenses/by/4.0 https://creativecommons.org/licenses/by/4.0 |
op_rightsnorm |
CC-BY |
op_doi |
https://doi.org/10.1038/s41408-021-00480-w |
container_title |
Blood Cancer Journal |
container_volume |
11 |
container_issue |
5 |
_version_ |
1766038332363505664 |